Long-Term Outcome of Aromatase Inhibitor Therapy With Letrozole in Patients With Advanced Low-Grade Endometrial Stromal Sarcoma

Yamaguchi, Masatoshi; Erdenebaatar, Chimeddulam; Saito, Fumitaka; Motohara, Takeshi; Miyahara, Yo; Tashiro, Hironori; Katabuchi, Hidetaka

doi:10.1097/igc.0000000000000557

Cited by 29 publications

(29 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a series of five patients treated with letrozole, durable partial response was obtained in all three cases administered AI as primary treatment and in one treated with MPA [26]. In another series of five patients treated with letrozole for unresectable peritoneal recurrent ESS two patients achieved complete responses lasting for 96 and 87 months [30]. These tumors were positive for ER, PgR and CD10, and negative for CD117.…”

Section: Endocrine Therapymentioning

confidence: 85%

See 1 more Smart Citation

Systemic therapy for endometrial stromal sarcomas: current treatment options

Serkies

Pawłowska²,

Jassem³

2016

Ginekol Pol

View full text Add to dashboard Cite

Uterine endometrial stromal sarcomas including true low-grade endometrial stromal sarcoma (LG-ESS) and high-grade (HG-ESS) or undifferentiated endometrial sarcoma (UES) constitute a group of rare, aggressive malignancies. Most LG-ESSs express steroid receptors. Surgery is the principal primary therapy for endometrial stromal sarcomas and should be considered in all cases. These malignancies are relatively radio-and chemoresistant. Chemotherapy is used in recurrent and advanced HG-ESS and UES. Currently, the combination of gemcitabine and docetaxel is considered the most effective regimen, but at the expense of substantial toxicity. In steroid receptor positive advanced LG-ESS hormonal therapy, mainly with progestins, allows in some patients for a long-term survival. Aromatase inhibitors seem to be equally effective as first-and subsequent-line of treatment, and are well tolerated. The role of molecular-targeted therapies in endometrial stromal sarcomas remains to be established.

show abstract

Section: Endocrine Therapymentioning

confidence: 85%

“…Data on the efficacy of AIs for ESS are scarce, with most published studies being case reports [23][24][25][26][27][28][29][30]. There is a report of complete responses lasting for more than 7 and 14 years in two patients with lung metastases treated with aminoglutethimide (500 mg bid) [28].…”

Section: Endocrine Therapymentioning

confidence: 99%

Systemic therapy for endometrial stromal sarcomas: current treatment options

Serkies

Pawłowska²,

Jassem³

2016

Ginekol Pol

View full text Add to dashboard Cite

show abstract

“…To the best of our knowledge, however, no patients with recurrent ESS who had undergone bilateral salpingo‐oophorectomy experienced CR or PR following treatment with GnRH analog alone. In contrast, aromatase inhibitors have induced CR or PR in several patients . Currently, we do not propose leuprorelin but propose letrozole for the treatment of recurrent ESS.…”

Section: Discussionmentioning

confidence: 98%

Effects of leuprorelin for the treatment of recurrent gynecological cancer by assessment including self‐administered quality‐of‐life questionnaire

Taniguchi

Ueda

Inoue

et al. 2018

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…Клинические исходы терапии были расценены как полный ответ у 2 боль-ных, частичный ответ у 1 пациентки и стабилизация заболевания у 2 пациенток. Миалгии, приливы и арт-ралгии не отмечены в течение периода наблюдения у всех пациентов [30].…”

Section: эндокринотерапия рака эндометрияunclassified

Aromatase inhibitors of the third generation in endocrine therapy of breast cancer and endometrial cancer: the successes and failures of the combination therapy

Fadeeva

Павловна²,

Lisyanskaya

et al. 2016

Rev Clin Pharm Drug Ther

View full text Add to dashboard Cite

Поступила в редакцию 12. 05.2016 Принята к печати 10. 06.2016 Ключевые слова:рак молочной железы; рак тела матки; лечение; ингибиторы ароматазы III поколения; тамоксифен. РезюмеОбзор обобщает современные данные клинических исследо-ваний, посвященных эффективности эндокринной терапии рака молочной железы и рака тела матки, включая эндоме- триальную стромальную саркому, ингибиторами аромата-зы (ИА) III поколения. В обзоре представлены данные кли-нических исследований, сравнивающих эффективность ИА и тамоксифена, а также данные о комбинированной терапии ИА с ингибиторами mTOR-пути (протокол BOLERO-2), с антиэстрогенами (протоколы SWOG S0226, FACT, FIRST), ингибитором CDK4/6 (протокол PALOMA-1) и другими пре-паратами. AROMATASE INHIBITORS OF THE THIRD GENERATION IN ENDOCRINE THERAPY OF BREAST CANCER AND ENDOMETRIAL CANCER: THE SUCCESSES AND FAILURES OF THE COMBINATION THERAPYKeywords:  breast cancer; endometrial cancer; therapy; aromatase inhibitors of III generation; tamoxifen. Abstract. This review provides the current evidence of clinical studies on the effectiveness of endocrine therapy for breast cancer and endometrial cancer, including endometrial stromal sarcoma, by aromatase inhibitor (AI) III generation. The review presents dates from clinical trials comparing the effectiveness of AI and tamoxifen, as well as dates on combination therapy AI with inhibitors of mTOR pathway (BOLERO-2 trial), an antiestrogen (SWOG S0226, FACT, FIRST trials), an inhibitor of CDK4 / 6 (PALOMA -1 trial) and other drugs. ВВЕДЕНИЕРак эндометрия (РЭ) представляет собой не толь-ко клиническую, но и социально-экономическую про-блему, так как инцидентность данного заболевания вместе с другими гормонально зависимыми опу-холями в Российской Федерации за последние не-сколько десятков лет увеличилась более чем в 2 раза, причем результаты лечения во многих регионах яв-ляются неудовлетворительными [1]. Новые техники хирургического лечения -активное тиражирование эндовидеохирургии -не улучшили отдаленные ре-зультаты лечения. В недавно выполненном под кон-тролем Gynecologic Oncology Group (GOG) проспек-

show abstract

Long-Term Outcome of Aromatase Inhibitor Therapy With Letrozole in Patients With Advanced Low-Grade Endometrial Stromal Sarcoma

Abstract: Letrozole as well as progestins could be the first choice of treatment for patients with recurrent or residual LGESS, which is difficult to resect surgically because of its efficacy and minimal adverse effects.

Cited by 29 publications

References 30 publications

Systemic therapy for endometrial stromal sarcomas: current treatment options

Systemic therapy for endometrial stromal sarcomas: current treatment options

Effects of leuprorelin for the treatment of recurrent gynecological cancer by assessment including self‐administered quality‐of‐life questionnaire

Aromatase inhibitors of the third generation in endocrine therapy of breast cancer and endometrial cancer: the successes and failures of the combination therapy

Contact Info

Product

Resources

About